TNF-alpha

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
Dimitrios A Pappas, Gregory St John, Carol J Etzel, Stefano Fiore, Taylor Blachley, Toshio Kimura, Rajeshwari Punekar, Kelechi Emeanuru, Jeannie Choi, Susan Boklage, Joel M Kremer

Annals of the Rheumatic Diseases Jan 2021, 80 (1) 96-102; DOI: 10.1136/annrheumdis-2020-217209
Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry
Pil Højgaard, Bente Glintborg, Merete Lund Hetland, Torben Højland Hansen, Philip Rask Lage-Hansen, Martin H Petersen, Mette Holland-Fischer, Christine Nilsson, Anne Gitte Loft, Bjarne Nesgaard Andersen, Thomas Adelsten, Jørgen Jensen, Emina Omerovic, Regitse Christensen, Ulrik Tarp, René Østgård, Lene Dreyer

Annals of the Rheumatic Diseases Dec 2015, 74 (12) 2130-2136; DOI: 10.1136/annrheumdis-2014-205389
FHL2 regulates the resolution of tissue damage in chronic inflammatory arthritis
Viktor Wixler, Christoph Cromme, Eugen Retser, Lars-Henrik Meyer, Neil Smyth, Katja Mühlenberg, Adelheid Korb-Pap, Christina Koers-Wunrau, Yannis Sotsios, Rhonda Bassel-Duby, Dominique Baeten, Paul P Tak, Birgit Niederreiter, Kurt Redlich, Jessica Bertrand, Boris V Skryabin, Stephan Ludwig, Thomas Pap

Annals of the Rheumatic Diseases Dec 2015, 74 (12) 2216-2223; DOI: 10.1136/annrheumdis-2013-205061
Progranulin protects against osteoarthritis through interacting with TNF-α and β-Catenin signalling
Yun-peng Zhao, Ben Liu, Qing-yun Tian, Jian-lu Wei, Brendon Richbourgh, Chuan-ju Liu

Annals of the Rheumatic Diseases Dec 2015, 74 (12) 2244-2253; DOI: 10.1136/annrheumdis-2014-205779
Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka et al
Lea C Berkhout, Merel J l'Ami, Gerrit Jan Wolbink, Theo Rispens

Annals of the Rheumatic Diseases Nov 2021, 80 (11) e172; DOI: 10.1136/annrheumdis-2019-216557
Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: to worry or not to worry?
Jasvinder A Singh

Annals of the Rheumatic Diseases Jul 2016, 75 (7) 1265-1267; DOI: 10.1136/annrheumdis-2015-208526
TNF-induced inflammatory genes escape repression in fibroblast-like synoviocytes: transcriptomic and epigenomic analysis
Christopher Loh, Sung-ho Park, Angela Lee, Ruoxi Yuan, Lionel B Ivashkiv, George D Kalliolias

Annals of the Rheumatic Diseases Sep 2019, 78 (9) 1205-1214; DOI: 10.1136/annrheumdis-2018-214783
Serum NT/CT SIRT1 ratio reflects early osteoarthritis and chondrosenescence
George Batshon, Jinan Elayyan, Omar Qiq, Eli Reich, Louisa Ben-Aderet, Leonid Kandel, Amir Haze, Jürgen Steinmeyer, Veronique Lefebvre, Hong Zhang, Jennifer Elisseeff, Yves Henrotin, Ali Mobasheri, Mona Dvir-Ginzberg

Annals of the Rheumatic Diseases Oct 2020, 79 (10) 1370-1380; DOI: 10.1136/annrheumdis-2020-217072
Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
Daniel Aletaha, Jen-fue Maa, Su Chen, Sung-Hwan Park, Dave Nicholls, Stefan Florentinus, Daniel Furtner, Josef S Smolen

Annals of the Rheumatic Diseases Dec 2019, 78 (12) 1609-1615; DOI: 10.1136/annrheumdis-2018-214918
Response to ’Correspondence to viewpoint ’Defining refractory rheumatoid arthritis' by Buch' by Roodenrijs et al
Maya H Buch

Annals of the Rheumatic Diseases Oct 2019, 78 (10) e106; DOI: 10.1136/annrheumdis-2018-214153

Main menu

TNF-alpha

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

TNF-alpha

Pages